Nosocomial or healthcare facility-related pneumonia in adults

Current Infectious Disease Reports

Volumn 2, Issue 3, 2000, Pages 215-223

  Balaguera, Henri U ^a   Mir, Julita ^a   Craven, Donald E ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

Clinical Pulmonary Infection Score; Infect Control Hosp; Intensive Care Unit Patient; Nosocomial Pneumonia; Respir Crit

Indexed keywords

EID: 0001708328     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-000-0038-4     Document Type: Article

References (47)

1. Craven DE, Steger KA, LaForce FM: Pneumonia. In Hospital Infections, edn 4. Edited by Bennett JV, Brachman PS. Philadelphia: Lippincott-Raven; 1997:487–513.
2. Vincent J-L, Bihari DJ, Suter PM, et al.: The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995, 274:639–644.
3. Kollef MH: The prevention of ventilator-associated pneumonia. N Engl J Med 1999, 340:627–634. The most current article with evidence-based recommendations for the prevention of HAP.
4. Tablan OC, Anderson LJ, Arden NH, et al.: Guideline for prevention of nosocomial pneumonia: Part I. Issues on prevention of nosocomial pneumonia, 1994. Infect Control Hosp Epidemiol 1994, 15:588–625.
5. Montecalvo MA, Jarvis WR, Uman J, et al.: Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999, 131:269–272.
6. Smith TL, Pearson ML, Wilcox KR, et al.: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999, 340:493–501.
7. Pallares R, Linares J, Vadillo M, et al.: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474–480.
8. Villers D, Espaze E, Coste-Burel M, et al.: Nosocomial Acinetobacter baumanii infections: microbiological and clinical epidemiology. Ann Intern Med 1998, 129:182–189. Excellent summary of the nosocomial infections caused by A. baumanii, an emerging and important respiratory tract pathogen.
9. Weber DJ, Rasch R, Rutala WA: Nosocomial infections in the ICU. Chest 1999, 115:34S-41S.
10. Thompson RS, Hall NK, Szpiech M: Hospitalization and mortality rates for nursing home-acquired pneumonia. J Fam Pract 1999, 48:291–293.
11. Muder RR: Pneumonia in residents of long-term care facilities: epidemiology, etiology, management and prevention. Am J Med 1998, 105:319–330.
12. Heyland DK, Cook DJ, Griffith L, et al.: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 1999, 159:1249–1256.
13. George DL, Falk PS, Wunderink RG, et al.: Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med 1998, 158:1839–1847.
14. Westendorp RGJ, Hottenga J, Stagboom PE: Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997, 349:170–173. Interesting data supporting the role of genetics in controlling tumor necrosis factor-a and interleukin-10 responses in relatives of patients who either lived or died from meningococcal infections.
15. Fagon JY, Chastre J, Hance AJ, et al.: Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993, 94:281–288.
16. Fagon J-Y, Chastre J, Domart Y, et al.: Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996, 23:538–542.
17. Greenaway CA, Embil J, Orr PF, et al.: Nosocomial pneumonia on general medical and surgical wards in a tertiary-care hospital. Infect Control Hosp Epidemiol 1997, 18:749–756.
18. Trouillet J-L, Chastre J, Vuagnat A, et al.: Ventilator-associated pneumonia caused by potentially drug resistant bacteria. Am J Respir Crit Care Med 1998, 157:531–539. A well-performed prospective study of the microbiology of VAP and associated risk factors, such as time of onset and prior antibiotic therapy.
19. Rello J, Sa-Borges M, Correa H, et al.: Variations in etiology of ventilator-associated pneumonia across four treatment sites. Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999, 160:608–613. A well performed prospective study of the microbiology of VAP and associated risk factors, such as time of onset and prior antibiotic therapy.
20. Drakulovic M, Torres A, Bauer T, et al.: Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomized trial. Lancet 1999, 354:1851–1858. Landmark randomized clinical study demonstrating that patients maintained in a semi-recumbent rather than supine body position had a reduced frequency of VAP, especially those who received enteral feeding. See the accompanying editorial by Dr. Webster.
21. Kollef MH, Skubas NJ, Sundt TM: A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. Chest 1999, 116:1339–1346.
22. Lysenko E, Gould J, Bals R, et al.: Mimicry of host membrane lipids by respiratory tract bacteria through expression of phosphorylcholine: effect on resistance to the antimicrobial peptide LL-37 found in the human nasopharynx [abstract]. 37th Annual Meeting of The Infectious Diseases Society of America, Philadelphia, 1999.
23. Karzai W, von Spect BU, Parent C, et al.: G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999, 159:1377–1382. Interesting study of the differences in response observed in a mouse model of pneumonia to challenge with E. coli versus S. aureus. See the accompanying editorial by Dr. Nelson.
24. Bonten MJM, Gaillard CA, de Leeuw PW, Stobberingh EE:The role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia. Clin Infect Dis 1997, 24:309–319.
25. Niederman MS, Craven DE: Devising strategies for nosocomial pneumonia prevention: should we ignore the stomach? Clin Infect Dis 1997, 24:320–323.
26. Luna C, Videla A, Mattera J, et al.: Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999, 116:1075–1084.
27. The American Thoracic Society: Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement. Am J Respir Crit Care Med 1995, 153:1711–1725.
28. Stockley RA: Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984–1994. Clin Infect Dis 1997, 25:195–199.
29. Pugin J, Auckenthaler R, Mili N, et al.: Diagnosis of ventilatorassociated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic blind bronchoalveolar lavage fluid. Am Rev Respir Dis 1988, 138:117–120.
30. Chastre J, Fagon JY: Invasive diagnostic testing should be routinely used to manage ventilated patients with suspected pneumonia. Am J Respir Crit Care Med 1994, 150:570–574.
31. Niederman MS, Torres A, Summer W: Invasive diagnostic testing is not needed routinely to manage suspect ventilatorassociated pneumonia. Am J Respir Crit Care Med 1994, 150:565–569.
32. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al.: Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998, 157:371–376. Important initial pilot study evaluating outcome in patients diagnosed with VAP by clinical criteria and quantitative endotracheal aspirates versus the use of bronchoscopy with BAL and PSB.
33. Timsit J-F, Chevret S, Valcke J, et al.: Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Am J Respir Crit Care Med 1996, 154:116–123.
34. Bregeon F, Papazian L, Visconti A, et al.: Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia. JAMA 1997, 277:655–662.
35. Meehan TP, Fine MJ, Krumholz HM, et al.: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080–2085.
36. Luna C, Vujacieh P, Niederman M, et al.: Impact of BAL data on the therapy and outcome of VAP. Chest 1997, 111:676–685. Important article with data supporting early, appropriate antibiotic therapy for ventilator-associated pneumonia.
37. Joshi M, Bernstein J, Solomkin J, et al.: Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infections. J Antimicrob Chemother 1999, 43:389–397.
38. Singh N, Rogers P, Atwood CA, et al.: Short-course empiric antibiotic therapy for suspected nosocomial pneumonia: a proposed solution for indiscriminate antibiotic prescription for pulmonary infiltrates in the ICU [abstract]. 36th Annual Meeting of the Infectious Disease Society of America, Denver, 1998.
39. Craven DE, Steger KA: Hospital-acquired pneumonia: perspectives for the epidemiologist. Infect Control Hosp Epidemiol 1997, 18:783–795.
40. Klein BS, Perloff WH, Maki DG, et al.: Reduction of nosocomial infection during pediatric intensive care by protective isolation. N Engl J Med 1989, 320:1714–1721.
41. Sirvent JM, Torres A, El-ebiary M, et al.: A protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med 1997, 155:1729–1734.
42. Cook DJ, Reeve BK, Guyatt GH, et al.: Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA 1996, 275:308–314.
43. Kollef MH, Vlasnik J, Sharpless L, et al.: Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:1040–1048.
44. Nichol KL, Baken L, Nelson A: Relation between influenza vaccination and outpatient visits, hospitalization and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999, 130:397–403. Important article supporting the effect of influenza vaccine in reducing patient hospitalization, outpatient visits, and mortality.
45. Eskola J, Antila M: Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999, 18:543–551. Excellent review of the new pneumococcal conjugate vaccine.
46. Knox RA: Nicotine vaccine takes aim at smoking addiction. Boston Globe 1999, December 17:3.
47. Osler W: The patient. In Sir William Osler Aphorisms: From His Bedside Teaching and Writings, edn 2. Edited by Benett W. Illinois: Charles C Thomas; 1961:106.